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Background: The choice of surgical or conservative treatment for patients with spontaneous intracerebral
hemorrhage is controversial. Some minimally invasive treatments have been applied to hematoma evacuation and
could improve prognosis to some extent. Up to now, studies on minimally invasive surgery for patients with
spontaneous intracerebral hemorrhage are still insufficient.
Design: The MISTICH is a multi-center, prospective, randomized, assessor-blinded, parallel group, controlled clinical
trial. 2448 eligible patients will be assigned to neuroendoscopy group, stereotactic aspiration group and craniotomy
group randomly. Patients will receive the corresponding surgery based on the result of randomization. Surgeries will
be performed by well-trained surgeons and standard medical treatment will be given to all patients. Patients will
be followed up at 7 days, 30 days, and 6 months. The primary outcome of this study is unfavorable outcome at 6
months. Secondary outcomes include: mortality at 30 days and 6 months after surgery; neurological functional
status of 6 months after surgery; complications including rebleeding, ischemic stroke and intracranial infection; days
of hospitalization.
Discussion: The MISTICH trial is a randomized controlled trial designed to determine whether minimally invasive
surgeries could improve the prognosis for patients with spontaneous intracerebral hemorrhage compared with
craniotomy. (ChiCTR-TRC-12002026. Registered 23 March 2012).
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Stereotactic aspirationBackground
Spontaneous intracerebral hemorrhage (sICH) is the
most devastate kind of all stokes. It was estimated that
sICH affects over 1 million people worldwide every year
[1,2]. The case fatality rate of sICH at 30 days is about
30%-55%, and only 12%-39% of the survivors could live
independently after 6 months [3-5].
The treatment of sICH is still controversial among
neurosurgeons and neurologists. The focus of debate is* Correspondence: ns_youchao@126.com
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unless otherwise stated.whether evacuation of hematoma would be able to improve
the prognosis of patients. Previous studies showed that the
removal of hematoma might reduce nervous tissue damage,
possibly by relieving local ischemia and removing noxious
chemicals [6-8]. Several studies aiming to explore the ef-
ficacy of surgery for patients with sICH have been carried
out but showed different results. In 1961, Mickissock and
colleagues published the first prospective randomized
controlled trial. Their results showed that patients treated
surgically had worse outcome than the patients in the
conservative group [9]. Another influential study is
the STICH series trials, which concluded that there
was no overall benefit of early surgery for patientsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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treatment [10,11]. Some researchers attributed this to
additional surgical traumatization. In order to reduce
surgical traumatization, some minimally invasive tech-
niques have been used in hematoma evacuation. These
minimally invasive techniques include stereotactic
aspiration and neuroendoscope assisted surgery. The
stereotactic aspiration guided by CT was successfully
applied for hematoma evacuation by Backlund and col-
logues at 1978, and this minimally invasive surgery was
further improved by some scholars [12]. It was reported
that the stereotactic aspiration combined with fibrinolytic
drugs could be more effective in hematoma evacuation
than aspiration alone [13]. Another category of minimally
invasive technique is neuroendoscope. Auer et al. reported
that neuroendoscope could be applied to hematoma evacu-
ation, but a subsequent randomized controlled trial showed
that the outcome of surgical patients with putaminal or
thalamic hemorrhage was not better than medical treat-
ment [14,15]. Recently, a lot of studies exploring the effi-
cacy of minimally invasive surgery (MIS) compared with
conservative craniotomy or medical treatment were carried
out, but none of them provided sufficient evidence regard-
ing the choice of treatment [16-20]. A further meta-analysis
showed that patients with supratentorial intracerebral
hemorrhage might benefit more from MIS than other treat-
ment options [21]. Though MIS seems less invasive than
the traditional craniotomy, it was reported that the inci-
dence of some complications (e.g. rebleeding and infection)
was higher than craniotomy. In addition, with assistance
of neuronavigation and operative microscope, hematoma
evacuation by craniotomy could also be minimally invasive
[22,23]. Until now, there is no randomized controlled trial
comparing the efficacy of neuroendoscopy, stereotactic
aspiration and craniotomy in patients with spontaneous
intracerebral hemorrhage except a small-scale trial by
Cho and colleges. Thus, a large-scale clinical trial is ne-
cessary to provide robust evidence for clinical practice
by assessing the safety and efficacy of different surgical
methods including neuroendoscopy, CT-stereotactic
aspiration and neuronavigation-assisted craniotomy for
sICH. Here we designed a randomized, assessor-blinded,
parallel-group, controlled, multi-center clinical study termed
minimally invasive surgery treatment for patients with
spontaneous supratentorial intracerebral hemorrhage
(MISTICH).
Design
The MISTICH is a multi-center, prospective, randomized,
assessor-blinded, parallel group, controlled clinical trial.
The overall flow of MISTICH is showed in Figure 1. A total
of 20 centers from around China are included. The centers
were eligible if they: have the ability to carry out all kinds
of minimally invasive surgery of this trial; demonstrateadequate trial experience; have previous adherence to
trial guidelines with high follow-up rates. All participating
hospital sites are to receive approval from the relevant
ethics committee before initiation of the study. Until now,
20 centers are currently involved with this study and all of
the centers have already received ethical approval. This
study has been registered in the Chinese Clinical Trial
Registry (ChiCTR-TRC-12002026). All the patients or their
legal surrogate will be fully informed and informed consent
will be signed in this trial.
Study objective
The primary objective is to evaluate different minimally
invasive techniques including neuronavigation assist
craniotomy, neuroendoscopy, and CT-stereotactic as-
piration on their unfavorable outcomes at 6 months in
patients with spontaneous intracerebral hemorrhage.
The secondary objective is to investigate the safety of
different minimally invasive techniques. Another objective
is to evaluate the separate effects of treatment on death
and dependency through physical function, complications,
and days of hospitalization.
Patient population
Inclusion criteria
(1)Age between 15 and 75 years;
(2)Diagnosed with acute spontaneous supratentotial
intracranial hemorrhage (Meets U.S. adults
spontaneous intracerebral hemorrhage treatment
guidelines (2010) diagnostic criteria)
(3)Within 48 hours post ictus;
(4)With Glasgow Coma Scale (GCS) between 5 and 12;
(5)CT scan showed hematoma volume is 30 ml or
above;
(6)Agree to participate in this clinic trial and sign the
informed consent.
Exclusion criteria
(1)The intracerebral hemorrhage is caused by
secondary factors (e.g. arteriovenous malformation;
aneurysm; tumor stroke);
(2)Concurrent head injury or history of head injury;
(3)Multiple intracranial hemorrhage;
(4)Known advanced dementia or disability before ICH
happened;
(5)With coagulation disorders or history of
anticoagulant drugs;
(6)With severe liver or kidney dysfunction;
(7)With indications of terminal brain hernia
(e.g. bilateral mydriasis and loss of light reflex,
serious disorders of the vital signs);
(8)Pregnancy;
Figure 1 Flow diagram of the MISTICH study.
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(CT scan shows that volume of hematoma in the
lateral ventricular is over 1/2 of ventricluar), or
lateral ventricular enlarge with third and fourth
ventricular hematoma.
Sample size
It was reported that the rate of poor outcome of patients
with a hemorrhage volume above 30 ml who received
craniotomy is about 49% to 67% [19,21,24]. Previous studies
showed that the MIS could decrease the rate of poor out-
come by about 7% to 22% [19,21] compared with craniot-
omy. We assume that the neuroendoscopy and stereotactic
aspiration can reduce the rate of poor outcome from 58%
to 51%, and a sample size of 2203 patients will be required
with a significance level of 5% (2-sided) and a power of
80%. In consideration of ensuring the quality of research,
the sample size is enlarged to 2448 (816 In each arm).
Randomization
Patients will be allocated to neuroendoscopy group,
stereotactic aspiration group and craniotomy group by
method of simple randomization. The randomized num-
ber was created before the trial by SPSS 19.0 and kept in
envelopes. The envelopes within randomized number
will be sent to the centers before trial begin.
Blinding
It was impossible to blind either the treating doctors or
patients in this trial. In order to ensure the quality of this
research, the assessors will be blinded. The outcomes of
patients will be measured and filled in paper Case Reports
Froms (CRF) by special researchers who would not take
part in the allocation and the treatment.
Treatment
After eligible patients are admitted to the hospital, the
investigator will collect the basic information of patients,
sign the informed consent and identify the randomizedassignment as soon as possible. For all the patients, best
medical treatments followed the recommendation of 2010
ASA/AHA intracerebral hemorrhage guidelines and preop-
erational preparation will be conducted at the same time.
The patients will receive the corresponding surgery based
on the result of randomization. All the surgeries will be
performed as soon as possible after the randomization.
Craniotomy
This group of patients will receive hematoma evacuation
by craniotomy. Well-trained neurosurgeons will decide
surgical approaches according to the result of neuronavi-
gation. The hematomas will be evacuated as much as pos-
sible with the help of operation microscope following the
principle of “no brain stretch, electrocoagulation with small
power, and slight aspiration”. A “Rebleeding test” will be
performed after hemostasis. For patients with hypertension,
the blood pressure will be slowly elevated to the level
before the anesthesia, and for other patients, a raise of
20 ~ 30 mmHg will be gained. The anesthetist will maintain
this level of blood pressure for 10 minutes. Only if there is
no new bleeding site, neurosurgeons can start to close.
Neuroendoscopic surgery
This group of patients will receive hematoma evacuation
by endoscopic surgery. Neurosurgeons will decide surgical
approaches according to the result of neuronavigation.
The hematomas will be evacuated as much as possible
with the help of angled endoscope, but the stiffly attached
clot won’t be removed by force in order to prevent un-
necessary damage, and the restricted intracavity operation
will be the principle during the hematoma evacuation.
“Rebleeding test” will be conducted before close.
Stereotactic aspiration
This group of patients will receive hematoma evacuation
by stereotactic aspiration. The puncture site will be based
on the result of neuronavigation aimed to avoid functional
domains and blood vessels. After puncture needlepoint
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fixed onto the skull. As much of the hematoma as possible
will be aspirated. Urokinase will be injected through the
puncture needle afterward. The dosage of urokinase is
based on the volume of hematoma (10000–50000 U). CT
scan will be performed immediately after the procedure.
Data collection and follow-up
After patient enrollment, we will collect their basic data
at neurological evaluation, functional status assessment
and imaging for baseline information, and follow up data
will be collected at the time of seven days, one month,
three months and six months after surgery. The plan of
data collection is showed in Table 1. All the data will be
recorded in the CRF in time. The filled CRF will be sent
to trial secretary expeditiously.
Outcomes
Primary outcome
The primary outcome of this study is the unfavorable
outcome at 6 months. The unfavorable outcome includes
death and dependency after randomization. The dependency
will be defined by using the Glasgow Outcome Scales
(GOS) at 6 months after randomization.
Secondary outcomes
The secondary outcomes include: mortality at 30 days,
and 6 months after surgery; neurological functional status
of 6 months after surgery measured by GOS, Modified
Rankin Scale (mRS), Barthe index (BI), and National
Institutes of Health Stroke Scale (NIHSS) separately;
complications include rebleeding, ischemic stroke, intracra-
nial infection; days of hospitalization.
CT scan
Pre-planned CT scan is at admitting, 1 day, 3 days, and
7 days after operation. Unplanned CT scan is decided
by the doctors if necessary. The volume of hematoma
is calculated by the formula A*B*C/2. Rebeeding is definedTable 1 Data collection program
Baseline 7 days 1 months 3 months 6 months
GCS √ √
GOS √ √ √
NIHSS √ √ √ √ √
mRS √ √ √
BI √ √ √
Laboratory
examination
√ √ √ √ √
Imaging √ √ √
GCS: Glasgow Coma Scale; GOS: Glasgow Outcome Scale; NIHSS: National
Institute of Health stroke scale; mRS: modified Rankin Scale; BI: Barthel Index.as the postoperative hematoma volume was either greater
than which before the operation or there was a less than
5-ml difference between the pre- and postoperative
hematoma volume measurement.
Statistical analysis
The “intension to treat” analysis will be applied in this
study. The descriptive analysis of all measurement data
is implemented using mean, standard deviation, median,
interquartile range, maximum and minimum indicators;
the descriptive analysis of count data is implemented using
index such as rate, ratio and RR. The primary analysis
will be a simple categorical frequency comparison for
unfavorable outcome by means of Chi-square test, so
will the categorical data of secondary outcomes. The
continuous outcomes will be analyzed by t-test. The
log-rank method will be used in the analysis of time-
to-event type of outcomes. Subgroup analysis stratified
by age, location of hematoma, volume of hematoma,
GCS at hospitalization, with/without intraventricular
hemorrhage, and midline shift is preplanned. Statistical
inference is conducted using the above-mentioned hy-
pothesis testing method and confidence interval may also
be used when necessary. P values ≤0.05 (α = 0.05) will be
considered statistically significant. All statistical analysis is
performed using SAS or SPSS statistical software.
Data and safety monitoring
An independent data and safety monitoring board (DSMB)
will monitor the safety and efficacy of this trial. The DSMB
consists of neurosurgeons, neurologists, radiologists, statis-
ticians, and data managers. Members of the DSMB will
meet in person twice a year to review the trial data. Interim
analyses will be conducted. The DSMB will stop the trial if
one of the treatments shows advantage or higher incidence
of severe adverse effect (SAE) than the other two at a very
high significance level (differences of more than 3 SD).
The adverse event (AE) is any undesirable syndrome of
enrolled patients happens during this study. The SAE
is defined as death and persistent vegetative state. Both
AEs and SAEs will be recorded in the CRF in detail. If
SAE happens, researchers must notify it to the DSMB in
24 hours.
Study organization
This study is initiated by Department of Neurosurgery
in West China Hospital, Sichuan University. West China
Hospital is a 4300-bed, superior large comprehen-
sive teaching and researching hospital in China. The
Department of Neurosurgery, founded in the 1950s, is
one of the earliest neurosurgery specialty wards in
China and the largest neurosurgery unit in Southwestern
China. A total of 20 centers will participate this study, and
the list of centers is showed in the acknowledgement.
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SICH has always been a frequently discussed topic in
neurology and neurosurgery. Though there are over 10
randomized studies aimed to find the best treatment for
patients with sICH, it is still very difficult to select indi-
vidualized treatment for each patient. MISTICH is the
first large-scale randomized, parallel-group clinical trial
to provide robust evidence for clinical practice by assessing
the safety and efficacy of different minimally invasive
surgical methods for sICH. A total of 2448 patients will
be enrolled in this study. The primary outcome is un-
favorable outcome at 6 months. The complications and
trends towards improved neurological outcome will also
be investigated in this study.
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